dromlakhani Conduct regular monitoring for testosterone therapy response and adverse events
STEP 1 — Gather Information
Collect baseline and follow‑up data: symptom assessment (libido, energy, mood, erectile function), adverse event review, total testosterone (tT), hematocrit, PSA, and perform digital rectal examination (DRE).
STEP 2 — Rule In / Rule Out
Is there an abnormal finding (hematocrit ≥54%, PSA rise ≥0.4 ng/mL, worsening hypogonadal symptoms, or no symptom improvement)?
- If yes, proceed to Step 3 to classify the abnormality.
- If no, continue current testosterone therapy and schedule the next routine visit per monitoring schedule (3 mo, 6 mo, then yearly).
STEP 3 — Classify or Stratify
Classify the abnormality:
| Finding | Mild | Moderate | Severe |
|---|---|---|---|
| Hematocrit | 54‑55% | 56‑60% | >60% |
| PSA change | 0.4‑1.0 ng/mL rise | >1.0 ng/mL rise or velocity >0.75 ng/mL/yr | Rapid rise or >2.0 ng/mL |
| Symptom response | Partial improvement | No improvement | Worsening |
| Based on the highest severity level, assign a grade. |
STEP 4 — Decide
Action based on classification:
- Mild: Repeat labs in 4‑6 weeks, consider lifestyle measures, continue same dose.
- Moderate: Reduce testosterone dose or change formulation, repeat labs in 4‑6 weeks, evaluate adherence.
- Severe: Hold testosterone therapy, investigate cause (e.g., polycythemia, prostate pathology), and consider specialist referral before restarting.
Clinical Guardrails / Mimics / Pitfalls
Do not ignore a rising hematocrit ≥54% as it increases thrombotic risk; do not delay PSA evaluation in men with baseline PSA >1.0 ng/mL or family history of prostate cancer; avoid continuing therapy if symptoms worsen without investigating non‑hormonal causes.
Concrete Clinical Example
A 58‑year‑old man starts testosterone gel 5 mg/day. At 3‑month visit, hematocrit is 56% (moderate), PSA unchanged, libido improved. Decision: reduce gel to 2.5 mg/day, recheck hematocrit in 6 weeks; if normal, maintain reduced dose.
Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036